Who Is at Risk of Testicular Cancer?

Understanding Testicular Cancer: Young Men's Disease, Treatable When Caught

Testicular cancer occupies a unique position in oncology. It is simultaneously the most common solid malignancy in men aged 15 to 35, and one of the most curable cancers in all of medicine — with an overall five-year survival rate exceeding 95%. This combination of youth-targeted incidence and high curability makes it a cancer where knowledge is genuinely life-saving. The difference between a good outcome and a catastrophic one often comes down to a single variable: how quickly a young man noticed a lump, reported it, and received diagnosis.

The testicles are paired oval organs located in the scrotum, responsible for producing testosterone and spermatozoa. They originate embryologically in the abdominal cavity and descend into the scrotum during fetal development — a migration that, when it goes wrong, becomes the single largest modifiable risk factor for the disease. Approximately 95% of testicular cancers are germ cell tumours, further divided into two major subtypes: seminomas, which tend to be slower-growing and appear in slightly older men with a peak incidence around age 35, and non-seminomas, which grow faster and predominate in men aged 15–30.

Perhaps the most concerning epidemiological trend is the rising incidence — rates have increased approximately 3.5-fold in developed countries over the past five decades, a pace too rapid to be explained by genetic change alone. This points firmly toward environmental and developmental factors, particularly those affecting the fetal and early postnatal testicular environment.

Testicular cancer kills young men who do nothing when they find a lump. It saves the lives of young men who act immediately. No other common cancer presents this stark a contrast between the consequences of action and inaction.

Who Is Most at Risk?

Testicular cancer is unusual among cancers because its dominant risk factors are largely developmental — rooted in conditions established before or shortly after birth — rather than lifestyle-driven. This does not mean risk is fixed and unaddressable. It means that awareness of developmental risk factors must drive surveillance and early detection. Testicular cancer risk is highly concentrated in young white men with a history of cryptorchidism or a family history of the disease. The presence of multiple risk factors compounds overall risk substantially.

Cryptorchidism: The Most Important Risk Factor

Cryptorchidism — the failure of one or both testicles to descend fully into the scrotum before birth — is the most consistently identified and strongest risk factor for testicular cancer, increasing risk 3 to 10 times above baseline. During normal fetal development, the testicles form near the kidneys and migrate downward through the inguinal canal into the scrotum in the final weeks of gestation. Disruption of any component of this hormonal signalling cascade can arrest descent.

Why an Undescended Testicle Is at Higher Risk

The scrotum maintains testicular temperature approximately 2–3 degrees Celsius below core body temperature. A testicle retained in the inguinal canal or abdomen is exposed to higher core body temperature throughout development, creating thermal stress on germ cells that impairs their maturation and increases DNA damage. Critically, the cancer risk in cryptorchidism appears to be rooted more fundamentally in the underlying gonadal dysgenesis — abnormal testicular tissue organisation from the outset — than in temperature alone.

Surgical correction of cryptorchidism, called orchidopexy, is standard care, ideally performed between 6 and 18 months of age. Early orchidopexy improves fertility outcomes and appears to modestly reduce cancer risk — studies suggest orchidopexy before age 13 is associated with approximately 2-fold elevated cancer risk, versus 5-fold for those treated after puberty. However, orchidopexy does not eliminate cancer risk entirely, as the underlying dysgenetic testicular tissue retains malignant potential regardless of its anatomical position after surgery.

The higher in the descent pathway the testicle is arrested, the greater the cancer risk. Intra-abdominal testicles carry higher risk than inguinal ones, which carry higher risk than high scrotal positions. Men with a history of cryptorchidism — whether corrected or not — require lifelong awareness of testicular cancer risk.

Family History, Genetics, and Hereditary Susceptibility

Testicular cancer has one of the strongest familial risk signals of any cancer. A man whose father has had testicular cancer carries approximately 4 to 6 times the population risk. A man with an affected brother carries an even higher relative risk — approximately 8 to 10 times — suggesting that shared genetic susceptibility variants are a more important driver than shared environmental exposures alone.

Despite this strong familial clustering, no single high-penetrance gene mutation analogous to BRCA1/2 for breast cancer has been identified. The genetic architecture appears to be polygenic, driven by a large number of common variants each contributing small increments of risk. Genome-wide association studies have identified more than 50 susceptibility loci, with the strongest signals in genes involved in germ cell biology and sex determination, including KITLG, SPRY4, BAK1, and DMRT1.

Bilateral Testicular Cancer: The Contralateral Risk

Men who have had testicular cancer in one testicle carry approximately 12 times the population risk of developing a second primary tumour in the contralateral testicle. The lifetime contralateral risk in men with prior testicular cancer is estimated at 2–5%, compared to a population lifetime risk of approximately 0.4%. This reflects the concept of testicular dysgenesis as a bilateral field defect — the same developmental disruption that produced one tumour has left the entire gonadal germline at elevated risk. Lifelong surveillance, including regular self-examination and periodic ultrasound in high-risk cases, is an integral part of follow-up care.

Germ Cell Neoplasia in Situ: The Direct Precursor

Germ cell neoplasia in situ (GCNIS) is the direct precursor lesion from which invasive testicular germ cell tumours develop — the testicular equivalent of cervical intraepithelial neoplasia. It is found in testicular biopsies in approximately 5% of men with cryptorchidism, 2–5% of men with a prior testicular cancer, and more than 8% of infertile men biopsied during workup. Left untreated, approximately 50–70% of GCNIS lesions will progress to invasive cancer within five years. GCNIS is therefore not a benign finding — it is an indication for active management, typically with low-dose radiotherapy to the affected testicle, surveillance, or orchiectomy depending on clinical context.

Ethnicity, Race, and the Geography of Testicular Cancer

Testicular cancer displays one of the most striking ethnic disparities of any cancer. White men of Northern European ancestry carry approximately 5 times the risk of Black men and approximately 3 times the risk of Asian men. In the United States, incidence rates are approximately 6–7 per 100,000 in non-Hispanic white men, compared to 1–1.5 per 100,000 in Black men. Incidence rates are highest globally in Scandinavia and Northern Europe, though no single environmental exposure has conclusively explained this geographic pattern.

While Black men are diagnosed with testicular cancer at much lower rates, they face worse outcomes when they are diagnosed — with higher rates of advanced-stage disease at presentation and lower survival rates. This pattern likely reflects disparities in health literacy about testicular self-examination, access to urological care, and clinical assumptions that may make providers less alert to testicular cancer in lower-incidence demographic groups. These are not inevitable biological outcomes — they are addressable gaps in equitable healthcare delivery.

Testicular Dysgenesis Syndrome: The Unifying Framework

The concept of Testicular Dysgenesis Syndrome represents the most intellectually coherent framework for understanding the interconnected risk factors for testicular cancer. It posits that cryptorchidism, hypospadias, impaired spermatogenesis, and testicular germ cell cancer are not four separate conditions but four clinical manifestations of a single underlying pathology: disturbed gonadal development during fetal life.

Disruption of normal Sertoli cell and Leydig cell function during the critical masculinisation programming window — approximately 8 to 22 weeks of gestation — leads to incomplete germ cell differentiation, abnormal testicular tissue organisation, and the retention of dysgenetic germ cells that retain malignant potential throughout life. This framework shifts the focus of testicular cancer prevention upstream — toward the prenatal and perinatal environment, maternal exposures, and the endocrine-disrupting chemical load of modern industrial society.

Men who present to infertility clinics with low or absent sperm counts carry approximately 2 to 3 times the population risk of testicular cancer. Infertility is a clinical marker of this syndrome, and men presenting with fertility problems warrant testicular cancer awareness counselling.

Tall Stature, Growth Factors, and Hormonal Environment

Among the epidemiological findings in testicular cancer is a robust association with taller stature. For every 5 centimetres of additional height, testicular cancer risk increases by approximately 10–13%. The mechanism is believed to involve IGF-1 signalling, which influences germ cell proliferation and survival in the testis and may delay the programmed death of dysgenetic germ cells, allowing precursor lesions to persist rather than be eliminated.

Several lines of evidence also point to the prenatal hormonal environment as a key determinant of risk. Low birth weight and preterm birth are associated with modest increases in testicular cancer risk, consistent with fetal androgen insufficiency impairing testicular development. Maternal exogenous oestrogen exposure during pregnancy — such as diethylstilboestrol prescribed historically for pregnancy support — is associated with increased testicular cancer risk in male offspring, providing direct human evidence for the endocrine disruption hypothesis.

Endocrine Disruptors, Occupation, and Environmental Exposures

The rising incidence of testicular cancer over the past 50 years has driven intense investigation into environmental exposures, particularly endocrine-disrupting chemicals that may impair the fetal hormonal environment during the critical masculinisation programming window. While no single chemical has been definitively proven to cause testicular cancer in humans, the evidence from animal studies, population-level epidemiology, and mechanistic research is convergent and concerning.

Organochlorine pesticides, polychlorinated biphenyls, perfluoroalkyl substances (PFAS), phthalates, and bisphenol A all exhibit oestrogen-mimicking or anti-androgenic activity and have been associated with testicular dysgenesis markers or elevated testicular cancer risk in various human and animal studies. The clearest human proof of concept comes from diethylstilboestrol, where male offspring of exposed mothers have elevated rates of both cryptorchidism and testicular cancer.

In occupational settings, the strongest associations in recent literature are with firefighters exposed to PFAS-containing fire-fighting foam, and with agricultural workers exposed to pesticides and herbicides. Military personnel stationed at PFAS-contaminated bases have also shown elevated rates in US military health studies.

HIV Infection, Klinefelter Syndrome, and Other Medical Risk Factors

HIV-positive men carry approximately 2 to 3 times the general population risk of testicular cancer, predominantly driven by seminoma. The association persists in the era of antiretroviral therapy, suggesting it is not simply a consequence of profound immunodeficiency.

Klinefelter syndrome — the most common sex chromosome aneuploidy, occurring in approximately 1 in 600 male births — results in small testes, impaired spermatogenesis, and testosterone deficiency. Men with Klinefelter syndrome carry markedly elevated risk for mediastinal germ cell tumours, with up to 50-fold elevated risk for this particular manifestation. Any unexplained mediastinal mass in a young man should prompt karyotype testing to exclude Klinefelter syndrome.

A history of inguinal hernia repair in childhood has been associated with approximately 2-fold elevated testicular cancer risk, most likely because it reflects the same underlying gonadal developmental abnormality that elevates testicular cancer risk, rather than the surgery itself causing harm.

Warning Signs Every Young Man Must Know

Testicular cancer is, in the vast majority of cases, a palpable disease. The tumour grows within the testis, distorting its shape and consistency in ways that are detectable by self-examination before systemic spread occurs. Yet the median delay between first noticing a symptom and seeking medical care is reported in multiple studies as 3 to 6 months — months in which a curable Stage I cancer may progress to more advanced disease.

Any new painless lump, firmness, or change in size or shape of a testicle is testicular cancer until proven otherwise. Do not wait for it to hurt — most testicular cancers do not hurt.

A painless lump or swelling within the substance of the testicle is the classic presentation. Diffuse testicular enlargement or change in consistency, a dull ache or heaviness in the scrotum or lower abdomen, and gynaecomastia — breast tissue development in men caused by elevated beta-hCG from some tumours — all warrant prompt evaluation. Back pain or an abdominal mass may indicate retroperitoneal lymph node metastases. Shortness of breath or cough in a young man may indicate pulmonary metastases. Sudden onset of scrotal pain, while less common, also requires urgent evaluation including ultrasound.

Testicular cancer caught at Stage I has a cure rate approaching 99%. Stage III disease, with distant metastases, has a cure rate of approximately 70%. Early detection is not just beneficial — it is transformative in terms of treatment burden, toxicity, and long-term quality of life.

Testicular Self-Examination: The Essential Skill

Testicular self-examination is the monthly practice of examining one's own testicles for new lumps, changes in consistency, or asymmetry. Most men who catch testicular cancer early do so through self-examination. It is best performed after a warm shower or bath, when the scrotal skin is relaxed, and takes under two minutes.

Cup the scrotum gently in both hands and note the overall weight and size — one testicle is often slightly larger or hangs lower than the other, which is normal. Using the thumb and first two fingers, gently roll each testicle between the fingers, feeling the entire surface. Locate the epididymis — the soft, cord-like structure attached to the back of each testicle — which is a normal structure and should not be mistaken for a lump. Feel for any hard lumps, firm areas, or changes in size or texture on the surface of the testicle itself. Repeat for the second testicle and compare the two.

If any new lump, area of firmness, or unexplained change is found, see a doctor that same week. The goal of self-examination is not diagnosis — it is detection. You are not trying to decide whether a finding is cancer. That decision belongs with a clinician and a scrotal ultrasound.

Common Myths vs. Facts

Myth: Testicular cancer is rare and won't happen to me.

Testicular cancer is the most common solid malignancy in men aged 15–35. In the 20–34 age bracket, it is the single most common cancer diagnosis for men. Young men are not exempt from serious cancer.

Myth: A lump on my testicle is probably just a cyst or injury — I'll wait and see.

The median delay from first symptom to medical presentation is 3–6 months. In that time, Stage I disease can progress to Stage II or III, requiring more aggressive treatment. A scrotal ultrasound can differentiate a benign epididymal cyst from an intratesticular malignancy within minutes. There is no safe period of watchful waiting for a new intratesticular finding.

Myth: My undescended testicle was fixed when I was a baby, so I no longer have any cancer risk.

Orchidopexy reduces but does not eliminate testicular cancer risk. The underlying gonadal dysgenesis persists in the testicular tissue regardless of its anatomical position. Men with corrected cryptorchidism have 2–5 times the population cancer risk for life.

Myth: Testicular cancer being a young man's disease means it's not serious.

Testicular cancer being a young man's disease makes the consequences of missed diagnosis more devastating in terms of life-years lost and impact on fertility, relationships, and career. It also makes it uniquely treatable — no cancer has better cure rates. The tragedy is not that it kills young men; it is that it sometimes does so unnecessarily due to delayed diagnosis.

Myth: Testicular cancer means I'll lose the ability to father children.

Many men successfully father children after testicular cancer treatment. Unilateral orchiectomy typically preserves fertility if the remaining testicle is healthy. Sperm banking before treatment is a well-established option that should be offered and strongly encouraged before any treatment begins.

Prevention, Risk Reduction, and Early Detection

Cryptorchidism should be corrected early in male children — current guidelines recommend orchidopexy between 6 and 18 months of age. Men with a history of cryptorchidism should be explicitly taught testicular self-examination and reminded of their lifelong elevated risk. Men with a father or brother with testicular cancer should begin monthly self-examination from puberty onward. Men diagnosed with male infertility should be advised of their modestly elevated testicular cancer risk, and testicular ultrasound should be considered as part of their workup.

Where environmental exposures are concerned, minimising exposure to endocrine-disrupting chemicals where practical — choosing BPA-free plastics, avoiding heating food in plastic containers, and using phthalate-free personal care products — is a reasonable precaution given the cumulative population-level evidence. Firefighters and other workers with PFAS exposure should use appropriate protective equipment and be particularly alert to testicular cancer symptoms.

Performing monthly testicular self-examination from puberty onward is the most important practical action any man can take. Any new intratesticular finding should prompt medical evaluation that same week — scrotal ultrasound is fast, non-invasive, and highly accurate. Men facing treatment should bank sperm before orchiectomy even if it precedes chemotherapy. Completing the full post-treatment surveillance protocol is not optional — recurrence is still highly treatable when detected through surveillance.

When to See a Doctor: The Diagnostic Pathway

The evaluation of a suspected testicular mass follows a well-established and highly efficient clinical pathway. Scrotal ultrasound is the first-line investigation, distinguishing intratesticular from extratesticular pathology with near-100% accuracy within minutes, involving no radiation. Serum tumour markers — beta-hCG, AFP, and LDH — are measured in all suspected cases and are essential for classification, staging, and follow-up, though normal markers do not exclude cancer.

If ultrasound and clinical findings are consistent with malignancy, surgical removal of the affected testicle through the inguinal approach provides definitive histological diagnosis and is simultaneously the primary treatment. The testicle should never be biopsied through the scrotum — this risks disrupting lymphatic drainage and upstaging the disease. Staging CT of the chest, abdomen, and pelvis follows orchiectomy to detect lymph node involvement and distant metastases.

Further management is tailored based on tumour histology, stage, and tumour marker levels: surveillance, retroperitoneal lymph node dissection, radiotherapy for early seminoma, or chemotherapy using the BEP regimen for more advanced disease. The entire pathway from scrotal ultrasound to orchiectomy can be completed within days in well-organised healthcare systems. If your healthcare provider is advising prolonged watchful waiting of an intratesticular lesion without tissue diagnosis, seek a second opinion from a urologist.

Unilateral orchiectomy leaves visible asymmetry that some men find psychologically distressing. Silicone testicular prostheses can be offered at the time of orchiectomy or later and are associated with high patient satisfaction. Psychological support should be a routine component of testicular cancer care, not an afterthought.

---

This document is intended for general health education and informational purposes only. It does not constitute medical advice, diagnosis, or treatment planning. If you have symptoms or concerns discussed in this document, please consult a physician without delay.